PPT Slide
Alfimeprase Phase 1 Successfully Completed
Design: Open label, single-dose, dose escalation study
Doses: 0.025, 0.05, 0.1, 0.3, and 0.5 mg/kg delivered as 5-15 minute infusions
Study conducted in 20 chronic patients in seven centers in the U.S.
Lead investigator, Dr. Kenneth Ouriel of the Cleveland Clinic
Endpoints: Drug tolerance
Occurrence of adverse events